Softomotive: Empowering Citizen Developers in Japan, South Korea and China Master RPA
16.12.2019 09:00:00 EET | Business Wire | Press release
Softomotive, the fastest growing Robotic Process Automation (RPA) provider trusted by over 9000 clients globally, announces the localization of its comprehensive free online RPA training to meet the increasing demand of Softomotive’s RPA solutions across 3 new markets: Japan, South Korea and Greater China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191215005029/en/
Softomotive expands Free online RPA training to 3 new markets: Japan, South Korea and Greater China. (Photo: Business Wire)
Together with the English version, Softomotive’s courses in RPA are now available in Japanese, Mandarin and Korean, with more local versions to come. WinAutomation users in Asia can now benefit from a more tailored experience and master RPA skills through the fully localized curriculum including the on-demand video courses, fact-sheets and quizzes.
“With the localized version of Softomotive’s RPA courses we are able to help even more developers and professionals master RPA skills covering Attended and UnAttended Automation.” says Marios Stavropoulos, Co-Founder and CEO for Softomotive. “By providing WinAutomation courses in Korean, Japanese, and Mandarin we are enabling the growth and adoption of RPA, making it much easier for organizations in those regions to train their employees as they seek to deploy and implement RPA”.
Continuing on its mission to improve the employability quotient of professionals and developers, Softomotive began working with channel partners who have both domain and linguistic expertise to improve the quality of the translations.
Several of our customers in South Korea and Japan also commented on the value of having localized courses on WinAutomation. One said that having Korean courses available is extremely helpful in educating employees and helping citizen developers start creating automations for the business much faster.
The official reveal of the localized courses was done in front of clients and partners in a series of events and meetings Seoul (South Korea), Tokyo (Japan) and Bengaluru (India). During these events, Softomotive’s leadership highlighted the role of Asia-Pacific region as one where RPA adoption is expected to see tremendous growth. The successful events and meetings served as a great platform to showcase how Softomotive’s People1st Approach to RPA, a bottom-up approach giving the power of automation to employees, is enabling businesses locally in South Korea, Japan and Greater China respond to the pressures of reduced labor productivity, following the recent regulations on working hours and work styles.
With the latest updates to the Softomotive Academy, learners from Japan, South Korea and China can obtain a Certification and Diploma in Robotic Process Automation.
Join
Entering the world of the Softomotive Academy is the first step to gaining credibility.
The online RPA learning portal provides an intuitive web-based interface that is accessible from any device (including mobile). Professionals can enroll and discover a rich catalogue of video-based RPA tutorials that support on-demand and self-paced learning on Attended and Unattended Automation.
Learn
Automation knowledge is fast becoming an essential skill set in the labor market.
The RPA Academy offers easy-to-follow individual courses helping learners to master RPA skills covering Attended and Unattended automation. Training ranges from a solid foundation on Robotic Desktop Automation (RDA) and enterprise RPA, to the development of complex process automation via scripting, and the advanced management and monitoring of software robots.
Grow
Receiving an Accreditation in Softomotive’s Process Automation solutions, learners become part of a global network of thousands of professionals already helping their respective organizations accelerate their digitization efforts. A Diploma in RPA enables professionals and developers stay ahead of the rest in this exciting industry. Learners can watch RPA courses at any time tailored for specific roles or can fully customize their learning experience based on their personal learning objectives.
Visit the Softomotive Academy to see the RPA courses in Japanese, Korean and Mandarin.
About Softomotive
Softomotive is one of the leading worldwide providers of Robotic Process Automation (RPA) solutions, trusted by more than 9,000 companies worldwide. Both attended and unattended RPA are delivered through powerful, robust RPA technology, from desktop installation to server-based software which is quick to deploy, easy to use and provides the best value for money
WinAutomation is the world’s best Robotic desktop automation (RDA) tool and provides a powerful, robust and easy to use Windows-based platform for building software robots.
ProcessRobot is a leading enterprise RPA platform, including enterprise grade security and controls, with links to best-of-breed AI technologies.
#ProcessRobot #Softomotive #WinAutomation
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191215005029/en/
Contact information
For more information:
Jesus Kallergis
Softomotive Press Office
Email@ press@softomotive.com
Tel: +44 207 048 2000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release
Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 11:27:00 EEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, where human creativity is renewed through technology. Leading the jury will be Gabriele Salvatores, Italian director and screenwriter known for films such as Nirvana, Siberian Education, and Napoli - New York, and Academy Award® winner for Best Foreign Language Film with Mediterraneo. Joining him on the panel for the third edit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom